This is an AMP page which is for mobile devices.

View Non AMP page

Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ABBV - Oruka jumps as lead drug outperforms AbbVie's Skyrizi in early-stage trial

ABBV - Oruka jumps as lead drug outperforms AbbVie's Skyrizi in early-stage trial

September, 17 2025 08:46 AM AbbVie Inc.

2025-09-17 08:46:48 ET

More on Oruka Therapeutics, AbbVie

AbbVie: Best Time To Sell In 5 Years (Rating Downgrade)
AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin
Short bets on S&P 500 Healthcare sector eases in August; MRNA stays most shorted stock
AbbVie settles with generic drugmakers for key immunology drug Rinvoq

For further details see:

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

Stock Information

Company Name:	AbbVie Inc.
Stock Symbol:	ABBV
Market:	NYSE
Website:	abbvieinvestor.com

Get ABBV Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.